Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
Sponsor: RayzeBio, Inc.
Summary
The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.
Official title: Phase 1 First-in-Human (FIH), Dose Escalation and Dose Expansion Study of RYZ401, a Novel Radiopharmaceutical Therapy Labeled With Actinium-225 (225Ac), in Subjects With Neuroendocrine Tumors (NETs) and Other Selected Solid Tumors Expressing Somatostatin Receptors (SSTRs).
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
104
Start Date
2025-10
Completion Date
2032-10
Last Updated
2025-09-10
Healthy Volunteers
No
Conditions
Interventions
RYZ401
Ac-225